EXEL

The article recommends two underrated biotech stocks: Axsome Therapeutics, which is experiencing strong growth with its drug Auvelity (51% YoY sales growth) and has a promising pipeline including potential new indications; and Exelixis, a cancer-focused biotech with a dominant drug Cabometyx protected until at least 2030, plus encouraging progress on pipeline candidates like zanzalintinib.

Exelixis (EXEL), an oncology-focused biotechnology company, is highlighted as a stock to watch with a Zacks Rank #3 (Hold) and VGM Score of A. The company demonstrates strong growth potential with a Growth Style Score of A and forecasted year-over-year earnings growth of 15.9% for the current fiscal year, supported by recent upward analyst revisions.

Exelixis (EXEL), a biomedical and genetics drug developer, has demonstrated a consistent pattern of beating earnings estimates over the last two quarters with an average surprise of 10.91%. The company's positive Earnings ESP of +2.44% combined with its Zacks Rank #3 (Hold) rating suggests another potential earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time.